Purinergic signaling (WP4900)

Homo sapiens

Authors

Friederike Ehrhart , Egon Willighagen , Eric Weitz , and Aishwarya Iyer

Activity

Discuss this pathway

Check for ongoing discussions or start your own.

Cited In

Are you planning to include this pathway in your next publication? See How to Cite and add a link here to your paper once it's online.

Organisms

Homo sapiens

Communities

Annotations

Pathway Ontology

nucleotide signaling via the purinergic P2Y receptors. nucleoside and nucleotide mediated signaling pathway

References

1. 2-Chloro-N6-[3H]cyclopentyladenosine ([3H]CCPA)--a high affinity agonist radioligand for A1 adenosine receptors. Klotz KN, Lohse MJ, Schwabe U, Cristalli G, Vittori S, Grifantini M. Naunyn Schmiedebergs Arch Pharmacol. 1989 Dec;340(6):679–83. PubMed Europe PMC Scholia
2. Enhancement of esophageal carcinogenesis induced in rats by N-amyl-N-methylnitrosamine in the presence of 12-O-tetradecanoylphorbol-13-acetate. Matsufuji H, Ueo H, Mori M, Kuwano H, Sugimachi K. J Natl Cancer Inst. 1987 Nov;79(5):1123–9. PubMed Europe PMC Scholia
3. Potent adenosine receptor antagonists that are selective for the A1 receptor subtype. Martinson EA, Johnson RA, Wells JN. Mol Pharmacol. 1987 Mar;31(3):247–52. PubMed Europe PMC Scholia
4. Adenosine receptors: development of selective agonists and antagonists. Daly JW, Jacobson KA, Ukena D. Prog Clin Biol Res. 1987;230:41–63. PubMed Europe PMC Scholia
5. Evaluation of the binding of the A-1 selective adenosine radioligand, cyclopentyladenosine (CPA), to rat brain tissue. Williams M, Braunwalder A, Erickson TJ. Naunyn Schmiedebergs Arch Pharmacol. 1986 Feb;332(2):179–83. PubMed Europe PMC Scholia
6. The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist. Zocchi C, Ongini E, Conti A, Monopoli A, Negretti A, Baraldi PG, et al. J Pharmacol Exp Ther. 1996 Feb;276(2):398–404. PubMed Europe PMC Scholia
7. Molecular physiology of P2X receptors. North RA. Physiol Rev. 2002 Oct;82(4):1013–67. PubMed Europe PMC Scholia
8. Novel N6-substituted adenosine 5’-N-methyluronamides with high selectivity for human adenosine A3 receptors reduce ischemic myocardial injury. Tracey WR, Magee WP, Oleynek JJ, Hill RJ, Smith AH, Flynn DM, et al. Am J Physiol Heart Circ Physiol. 2003 Dec;285(6):H2780-7. PubMed Europe PMC Scholia
9. Partial A(1) adenosine receptor agonists from a molecular perspective and their potential use as chronic ventricular rate control agents during atrial fibrillation (AF). Zablocki JA, Wu L, Shryock J, Belardinelli L. Curr Top Med Chem. 2004;4(8):839–54. PubMed Europe PMC Scholia
10. The future of pharmacologic stress: selective A2A adenosine receptor agonists. Cerqueira MD. Am J Cardiol. 2004 Jul 22;94(2A):33D-40D; discussion 40D-42D. PubMed Europe PMC Scholia
11. A(1) adenosine receptor agonists: medicinal chemistry and therapeutic potential. Hutchinson SA, Scammells PJ. Curr Pharm Des. 2004;10(17):2021–39. PubMed Europe PMC Scholia
12. In vivo imaging of adenosine A2A receptors in rat and primate brain using [11C]SCH442416. Moresco RM, Todde S, Belloli S, Simonelli P, Panzacchi A, Rigamonti M, et al. Eur J Nucl Med Mol Imaging. 2005 Apr;32(4):405–13. PubMed Europe PMC Scholia
13. Adenosine A2A receptors mediate GABAergic inhibition of respiration in immature rats. Mayer CA, Haxhiu MA, Martin RJ, Wilson CG. J Appl Physiol (1985). 2006 Jan;100(1):91–7. PubMed Europe PMC Scholia
14. ZM241385, DPCPX, MRS1706 are inverse agonists with different relative intrinsic efficacies on constitutively active mutants of the human adenosine A2B receptor. Li Q, Ye K, Blad CC, den Dulk H, Brouwer J, Ijzerman AP, et al. J Pharmacol Exp Ther. 2007 Feb;320(2):637–45. PubMed Europe PMC Scholia
15. Recent improvements in the development of A(2B) adenosine receptor agonists. Baraldi PG, Tabrizi MA, Fruttarolo F, Romagnoli R, Preti D. Purinergic Signal. 2008 Dec;4(4):287–303. PubMed Europe PMC Scholia
16. Cognitive enhancers (nootropics). Part 1: drugs interacting with receptors. Froestl W, Muhs A, Pfeifer A. J Alzheimers Dis. 2012;32(4):793–887. PubMed Europe PMC Scholia
17. Glutathione-Induced Calcium Shifts in Chick Retinal Glial Cells. Freitas HR, Ferraz G, Ferreira GC, Ribeiro-Resende VT, Chiarini LB, do Nascimento JLM, et al. PLoS One. 2016 Apr 14;11(4):e0153677. PubMed Europe PMC Scholia
18. Glutathione induces GABA release through P2X7R activation on Müller glia. Freitas HR, Reis RA de M. Neurogenesis (Austin). 2017 Feb 6;4(1):e1283188. PubMed Europe PMC Scholia
19. BLU-5937: A selective P2X3 antagonist with potent anti-tussive effect and no taste alteration. Garceau D, Chauret N. Pulm Pharmacol Ther. 2019 Jun;56:56–62. PubMed Europe PMC Scholia
20. Action of MK-7264 (gefapixant) at human P2X3 and P2X2/3 receptors and in vivo efficacy in models of sensitisation. Richards D, Gever JR, Ford AP, Fountain SJ. Br J Pharmacol. 2019 Jul;176(13):2279–91. PubMed Europe PMC Scholia
21. Update on novel purinergic P2X3 and P2X2/3 receptor antagonists and their potential therapeutic applications. Marucci G, Dal Ben D, Buccioni M, Martí Navia A, Spinaci A, Volpini R, et al. Expert Opin Ther Pat. 2019 Dec;29(12):943–63. PubMed Europe PMC Scholia